SK BioscienceSK바이오사이언스
302440 · KOSPI · ₩302440 · SK바이오사이언스
₩32,150▲ ₩400 (1.26%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 14.3% | 11.7% | 11.6% | 38.5% | 52.5% | 61.4% |
| Operating margin | −19.9% | −19.0% | −51.7% | −3.2% | 25.2% | 51.0% |
| Net margin | −12.8% | −8.8% | −20.1% | 6.0% | 26.8% | 38.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +1.2% | +143.5% | −27.6% | −19.1% | −50.8% | — |
| Operating income growth | −6.3% | +10.8% | −1,054.8% | −110.4% | −75.7% | — |
| Net income growth | −47.5% | −6.6% | −341.4% | −81.8% | −65.5% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −4.8% | −3.2% | −3.1% | 1.3% | 7.3% | 22.2% |
| Return on assets | −1.8% | −1.9% | −2.1% | 1.1% | 5.8% | 16.8% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 48.6% | 45.1% | 40.6% | 8.7% | 23.0% | 31.8% |
| Net debt to equity | −15.2% | −21.7% | −38.3% | −74.8% | −8.1% | −0.2% |
| Current ratio | 360.1% | 382.0% | 507.6% | 1,019.7% | 469.3% | 399.6% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: SK Bioscience / SK바이오사이언스 / 302440 / KRX:302440
Source: KRX statistical information